Cerus Corp. Rating Reiterated by Cantor Fitzgerald (CERS)
Cerus Corp. (NASDAQ:CERS)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a research note issued on Monday, StockRatingsNetwork.com reports. They currently have a $7.00 price target on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 82.29% from the company’s current price.
Cerus Corp. (NASDAQ:CERS) traded up 2.73% on Monday, hitting $3.945. The stock had a trading volume of 598,460 shares. Cerus Corp. has a 52 week low of $3.74 and a 52 week high of $8.00. The stock’s 50-day moving average is $4.82 and its 200-day moving average is $6.03. The company’s market cap is $284.4 million.
Cerus Corp. (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The company had revenue of $7.86 million for the quarter, compared to the consensus estimate of $9.65 million. The company’s revenue for the quarter was down 19.2% on a year-over-year basis. On average, analysts predict that Cerus Corp. will post $-0.50 earnings per share for the current fiscal year.
Separately, analysts at MLV & Co
cut their price target on shares of Cerus Corp. from $8.50 to $6.00 in a research note on Friday. They now have a “buy” rating on the stock.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.